[{"orgOrder":0,"company":"Microbio","sponsor":"Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SNS812","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"8","companyTruncated":"Microbio \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"Microbio","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"MBS","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"Microbio","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Microbio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : MS-20 is a postbiotic produced through the symbiotic fermentation of multi-strain probiotics. It is being investigated for immunological and gastrointestinal diseases.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : MS-20,Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : SNS812 achieves statistical significance with clinically meaningful endpoints in the Phase 2 trial and is the only therapeutic with a broad-spectrum efficacy in multiple coronavirus variants.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2024

                          Lead Product(s) : SNS812

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Oneness Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 01, 2021

                          Lead Product(s) : MS-20

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : National Taiwan University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 01, 2021

                          Lead Product(s) : MS-20

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          December 19, 2020

                          Lead Product(s) : MS-20

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          November 20, 2020

                          Lead Product(s) : MBS

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          October 23, 2020

                          Lead Product(s) : MS-20

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : National Taiwan University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 01, 2015

                          Lead Product(s) : MB-110

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 13, 2010

                          Lead Product(s) : MB-6

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank